Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

10 clinical studies listed.

Filters:

Poly Cystic Ovary Syndrome

Tundra lists 10 Poly Cystic Ovary Syndrome clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

COMPLETED

NCT07874646

Efficacy of Metformin With and Without Probiotics in Women With PCOS

This prospective interventional study evaluated the effectiveness of metformin alone compared with metformin combined with probiotics in women with polycystic ovary syndrome (PCOS). The study included women aged 18-45 years diagnosed with PCOS according to the Rotterdam criteria. Participants received either metformin alone or metformin combined with probiotic supplementation for 12 weeks. The study assessed changes in hormonal parameters such as total testosterone (TT), sex hormone-binding globulin (SHBG), and free androgen index (FAI) to determine whether adding probiotics to metformin provided additional benefits in the management of PCOS.

Gender: FEMALE

Ages: 18 Years - 45 Years

Updated: 2026-10-15

1 state

Poly Cystic Ovary Syndrome
ACTIVE NOT RECRUITING

NCT07871175

Inspiratory Muscle Training for the Management of Polyendocrine Metabolic Ovarian Syndrome

Inspiratory muscle training (IMT) is a relatively simple and accessible form of exercise that specifically targets the respiratory muscles and has been reported to improve inspiratory muscle strength, respiratory efficiency, exercise capacity, and autonomic cardiovascular regulation in different populations. Given the close relationship between respiratory muscle function, exercise capacity, autonomic regulation, and metabolic health, IMT may represent a potentially useful adjunctive intervention for women with PCOS. Therefore, investigating the effects of inspiratory muscle training on relevant metabolic, functional, and clinical outcomes in women with PCOS may provide an additional therapeutic approach within physiotherapy and lifestyle-based management.

Gender: FEMALE

Ages: 20 Years - 30 Years

Updated: 2026-10-13

1 state

Poly Cystic Ovary Syndrome
RECRUITING

NCT07706374

E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study

The goal of this clinical trial is to learn if study drug exemestane will increase chances of ovulation for patients with polyendocrine metabolic ovarian syndrome (PMOS, formerly called polycystic ovary syndrome (PCOS)). It will also learn about side effects of study drug exemestane in this study population. The main questions it aims to answer are: Does exemestane lead to ovulation for patients with polyendocrine metabolic ovarian syndrome (PMOS- formerly called PCOS)? Researchers will compare exemestane to a placebo (a look-alike substance that contains no drug) to see if exemestane helps PMOS patients ovulate. Participants will: Take exemestane or a placebo every day for 5-10 days Visit the clinic three times for ultrasounds, labs, and to answer questions about side effects. If they become pregnant during this study, they will tell us how their pregnancy went after the study via a registry online.

Gender: FEMALE

Ages: 18 Years - 40 Years

Updated: 2026-09-23

1 state

Poly Cystic Ovary Syndrome
NOT YET RECRUITING

NCT07811011

Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, with insulin resistance playing a central role in its pathophysiology. Hyperinsulinemia can enhance ovarian androgen production and reduce hepatic sex hormone-binding globulin synthesis, thereby aggravating hyperandrogenism and reproductive abnormalities. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances endogenous incretin activity and may improve insulin sensitivity and glucose homeostasis. Emerging evidence suggests that DPP-4 inhibition may also influence body weight, androgen excess, inflammation, and reproductive function in women with PCOS.

Gender: FEMALE

Ages: 18 Years - 40 Years

Updated: 2026-09-21

Poly Cystic Ovary Syndrome
ACTIVE NOT RECRUITING

NCT07821073

Myo-Inositol and Folic Acid for Improving Inflammation in Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS) is a common endocrine and metabolic disorder affecting women of reproductive age and may be associated with chronic low-grade systemic inflammation. This clinical trial aims to evaluate the combined effect of Myo-Inositol and Folic Acid on systemic inflammatory markers, specifically the Neutrophil-to-Lymphocyte Ratio (NLR) and C-reactive protein (CRP), in women with PCOS. The study will compare the effects of Myo-Inositol plus Folic Acid with Metformin plus Folic Acid over a 3-month treatment period. Eligible participants will be randomly assigned to one of the two treatment groups and will take their assigned treatment daily for 3 months. Participants will attend monthly follow-up visits to assess treatment adherence, clinical progress, and any adverse effects. Blood samples will be collected at baseline and after completion of the 3-month intervention to measure NLR and CRP. Participants will also be instructed to record relevant symptoms and report any side effects experienced during the study. The primary purpose of the study is to determine whether Myo-Inositol and Folic Acid reduce NLR and CRP compared with Metformin and Folic Acid in women with PCOS.

Gender: FEMALE

Ages: 25 Years - 35 Years

Updated: 2026-09-15

1 state

Inflammation Biomarkers
Poly Cystic Ovary Syndrome
PCOS (Polycystic Ovary Syndrome)
NOT YET RECRUITING

NCT07810998

Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome

In PCOS (Polycystic Ovary Syndrome), studies have found impaired incretin secretion and activity, particularly in overweight/obese individuals. Conflicting results exist regarding glucagon-like peptide-1(GLP-1) levels in PCOS patients, with studies reporting reduced, normal, or increased levels. Incretin-based therapy has been suggested as a potential treatment to reverse prediabetes risk by preserving β-cell function in patients with impaired fasting glucose(IFG and impaired glucose tolerance(IGT).

Gender: FEMALE

Ages: 18 Years - 40 Years

Updated: 2026-09-09

Poly Cystic Ovary Syndrome
NOT YET RECRUITING

NCT07659392

Physical Activity and Cardiometabolic Health in Women With or Without Polycystic Ovary Syndrome (SCOPAP)

The primary objective of this study is to investigate the effects of a multidisciplinary intervention, including a targeted adapted physical activity program, on lipid oxidation during a walking exercise in women with overweight or obesity, with or without polycystic ovary syndrome. Specifically, the study aims to compare changes in lipid oxidation before and after the intervention between women with polycystic ovary syndrome and those without polycystic ovary syndrome. The secondary objectives are to assess the impact of polycystic ovary syndrome on several physiological and metabolic parameters in women with overweight or obesity. These include: (i) resting energy metabolism; (ii) resting blood pressure and heart rate; (iii) energy expenditure, energy cost, and heart rate during a walking exercise; (iv) body composition, glycemic and lipid profiles, and circulating levels of sex hormones and adipokines; (v) movement behaviors; and (vi) physical fitness. In addition, the effect of the multidisciplinary intervention, including the adapted physical activity program, will be evaluated on these same outcomes: (i) resting energy metabolism; (ii) resting blood pressure and heart rate; (iii) energy expenditure, energy cost, and heart rate during walking exercise; (iv) body composition, glycemic and lipid profiles, and concentrations of sex hormones and adipokines; (v) movement behaviors; and (vi) physical fitness, in women with overweight or obesity, with or without polycystic ovary syndrome.

Gender: FEMALE

Ages: 18 Years - 40 Years

Updated: 2026-06-22

Poly Cystic Ovary Syndrome
Overweight , Obesity
RECRUITING

NCT07630779

Efficacy of Alpha Lipoic Acid Combined With Myo-Inositol in Non-Diabetic PCOS Patients

This study evaluates the efficacy of alpha-lipoic acid combined with myo-inositol, with or without metformin, in improving menstrual regularity and ovulation in non-diabetic women with polycystic ovary syndrome (PCOS). The study also assesses metabolic, hormonal, and clinical outcomes.

Gender: FEMALE

Ages: 21 Years - 40 Years

Updated: 2026-06-05

1 state

Poly Cystic Ovary Syndrome
COMPLETED

NCT07586969

Modulation of Hyperandrogenic Anovulation Through Fenugreek Seeds

Hyperandrogenic anovulation is a common gynecological illness that impacts the ovaries, vagina and uterus. According to Statistics, in Pakistan 17.6% of individuals seeking treatment at infertility clinics were found to be affected by hyperandrogenic anovulation. Studies indicate that fenugreek seeds have the potential to improve insulin sensitivity, control hormone levels, namely the increased androgens linked to hyperandrogenic anovulation, and promote ovulation, a process commonly interrupted in individuals with hyperandrogenic anovulation. In order to create a therapy plan that is both affordable and easily accessible for women who suffer from hyperandrogenic anovulation, this study aims to determine the therapeutic efficacy of fenugreek seed powder in reducing symptoms related to the illness. Furthermore, it aims to increase knowledge on the extensive utilization of fenugreek seed powder as a natural treatment for hyperandrogenic anovulation.

Gender: FEMALE

Ages: 15 Years - 25 Years

Updated: 2026-05-28

Poly Cystic Ovary Syndrome
RECRUITING

NCT06142656

Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet and physical activity that are the first-line approach to treatment; however, they are reported to be minimally effective in reducing weight or treating PCOS-related symptoms.Pharmacological options are also available; however, they are not explicitly approved for PCOS treatment as they have been primarily used to treat other conditions such as T2DM

Gender: FEMALE

Ages: 18 Years - 50 Years

Updated: 2025-07-30

Poly Cystic Ovary Syndrome